Calidi Biotherapeutics, Inc. (CLDI)
NYSEAMERICAN: CLDI · Real-Time Price · USD
1.460
-0.080 (-5.19%)
Dec 5, 2025, 4:00 PM EST - Market closed
Calidi Biotherapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Net Income | -19.95 | -22.14 | -29.22 | -25.43 | -10.93 | -7.94 |
| Depreciation & Amortization | 1.62 | 1.54 | 1.26 | 0.26 | 0.16 | 0.11 |
| Other Amortization | 0 | 0.05 | 0.43 | 0.12 | 0.56 | 0.08 |
| Loss (Gain) From Sale of Assets | - | - | 0.01 | - | - | - |
| Asset Writedown & Restructuring Costs | - | - | - | - | 0.17 | - |
| Stock-Based Compensation | 2.28 | 2.96 | 4.81 | 4.52 | 1.33 | 0.97 |
| Other Operating Activities | -0.17 | -0.39 | 1.97 | 3.74 | -0.15 | 1.01 |
| Change in Accounts Payable | -2.09 | -0.63 | -6.17 | 1.62 | -0.24 | 0.29 |
| Change in Other Net Operating Assets | -3.38 | -1.07 | -0.07 | 1.95 | 1.34 | 0.65 |
| Operating Cash Flow | -21.67 | -19.69 | -26.98 | -13.21 | -7.77 | -4.83 |
| Capital Expenditures | -0.1 | -0.02 | -0.59 | -0.43 | -0.21 | -0.35 |
| Cash Acquisitions | - | - | 0.01 | - | - | - |
| Other Investing Activities | - | - | 0.1 | -0.07 | -0.01 | -0.04 |
| Investing Cash Flow | -0.1 | -0.02 | -0.48 | -0.49 | -0.22 | -0.39 |
| Short-Term Debt Issued | - | 0.8 | 3.25 | 1.5 | 1.5 | 0.6 |
| Long-Term Debt Issued | - | 3 | - | - | 0.38 | 1.44 |
| Total Debt Issued | - | 3.8 | 3.25 | 1.5 | 1.88 | 2.04 |
| Short-Term Debt Repaid | - | -0.3 | -1.3 | -0.04 | -0.1 | -0.1 |
| Long-Term Debt Repaid | - | -1.58 | -1.05 | -0.08 | -0.03 | -0.06 |
| Total Debt Repaid | -2.48 | -1.88 | -2.35 | -0.12 | -0.13 | -0.16 |
| Net Debt Issued (Repaid) | -2.48 | 1.92 | 0.9 | 1.38 | 1.75 | 1.88 |
| Issuance of Common Stock | 29.8 | 22.87 | 0.28 | 0.11 | 0.14 | 3 |
| Other Financing Activities | 2.91 | 2.58 | 3.37 | 10.59 | 7.93 | -0 |
| Financing Cash Flow | 30.23 | 27.37 | 29.04 | 12.09 | 9.81 | 4.7 |
| Foreign Exchange Rate Adjustments | 0.02 | -0.01 | -0.01 | -0.03 | -0 | 0 |
| Net Cash Flow | 8.48 | 7.64 | 1.58 | -1.65 | 1.82 | -0.51 |
| Free Cash Flow | -21.77 | -19.71 | -27.57 | -13.64 | -7.98 | -5.18 |
| Free Cash Flow Margin | - | - | - | -30315.56% | -1777.28% | - |
| Free Cash Flow Per Share | -7.67 | -29.55 | -196.22 | -192.49 | -48.49 | -36.26 |
| Cash Interest Paid | 0.86 | 0.14 | 0.4 | 0.04 | 0.05 | 0.02 |
| Cash Income Tax Paid | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0 |
| Levered Free Cash Flow | -13.04 | -11.21 | -43.96 | 6.74 | 12.15 | - |
| Unlevered Free Cash Flow | -12.83 | -10.68 | -43.72 | 6.72 | 11.97 | - |
| Change in Working Capital | -5.47 | -1.7 | -6.24 | 3.57 | 1.1 | 0.95 |
Source: S&P Capital IQ. Standard template.
Financial Sources.